(5-甲基异噻唑-3-基)甲基甲磺酸负离子 | 783325-24-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: (5-甲基异噻唑-3-基)甲基甲磺酸负离子
• 英文名称: (5-methylisoxazol-3-yl)methyl methanesulfonate
• 英文别名: methanesulfonic acid 5-methyl-isoxazol-3-ylmethyl ester；(5-methyl-1,2-oxazol-3-yl)methyl methanesulfonate
• CAS: 783325-24-6
• 化学式: C₆H₉NO₄S
• 分子量: 191.208
• InChiKey: JDIWPWGJSKETBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  77.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (5-甲基异噻唑-3-基)甲基甲磺酸负离子 在 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 31.67h， 生成 (R)-2,4-dihydroxy-3,3-dimethyl-N-(3-((2-(2-(((5-methylisoxazol-3-yl)methyl)thio)acetamido)ethyl)amino)-3-oxopropyl)butanamide
  参考文献：
  名称：

  Modeling Linear and Cyclic PKS Intermediates through Atom Replacement

  摘要：

  The mechanistic details of many polyketide synthases (PKSs) remain elusive due to the instability of transient intermediates that are not accessible via conventional methods. Here we report an atom replacement strategy that enables the rapid preparation of polyketone surrogates by selective atom replacement, thereby providing key substrate mimetics for detailed mechanistic evaluations. Polyketone mimetics are positioned on the actinorhodin acyl carrier protein (actACP) to probe the underpinnings of substrate association upon nascent chain elongation and processivity. Protein NMR is used to visualize substrate interaction with the actACP, where a tetraketide substrate is shown not to bind within the protein, while heptaketide and octaketide substrates show strong association between helix II and IV. To examine the later cyclization stages, we extended this strategy to prepare stabilized cyclic intermediates and evaluate their binding by the actACP. Elongated monocyclic mimics show much longer residence time within actACP than shortened analogs. Taken together, these observations suggest ACP-substrate association occurs both before and after ketoreductase action upon the fully elongated polyketone, indicating a key role played by the ACP within PKS timing and processivity. These atom replacement mimetics offer new tools to study protein and substrate interactions and are applicable to a wide variety of PKSs.

  DOI：

  10.1021/ja5064857
• 作为产物：
  描述：

  5-甲基异恶唑-3-羧酸甲酯 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 5.5h， 生成 (5-甲基异噻唑-3-基)甲基甲磺酸负离子
  参考文献：
  名称：

  Modeling Linear and Cyclic PKS Intermediates through Atom Replacement

  摘要：

  The mechanistic details of many polyketide synthases (PKSs) remain elusive due to the instability of transient intermediates that are not accessible via conventional methods. Here we report an atom replacement strategy that enables the rapid preparation of polyketone surrogates by selective atom replacement, thereby providing key substrate mimetics for detailed mechanistic evaluations. Polyketone mimetics are positioned on the actinorhodin acyl carrier protein (actACP) to probe the underpinnings of substrate association upon nascent chain elongation and processivity. Protein NMR is used to visualize substrate interaction with the actACP, where a tetraketide substrate is shown not to bind within the protein, while heptaketide and octaketide substrates show strong association between helix II and IV. To examine the later cyclization stages, we extended this strategy to prepare stabilized cyclic intermediates and evaluate their binding by the actACP. Elongated monocyclic mimics show much longer residence time within actACP than shortened analogs. Taken together, these observations suggest ACP-substrate association occurs both before and after ketoreductase action upon the fully elongated polyketone, indicating a key role played by the ACP within PKS timing and processivity. These atom replacement mimetics offer new tools to study protein and substrate interactions and are applicable to a wide variety of PKSs.

  DOI：

  10.1021/ja5064857

文献信息

• Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists
  申请人：Bissantz Caterina

  公开号：US20070027173A1

  公开（公告）日：2007-02-01

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哚-3-基-甲酰基-螺环-哌啶衍生物，其由公式I表示：其中，螺环-哌啶头基A以及残基R1、R2和R3如本文所述定义。本发明进一步涉及含有此类化合物的药物组合物，制备化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、血管升压素不适当分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁障碍中的用途。
• 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof
  申请人：Uchida Masahiko

  公开号：US20050014787A1

  公开（公告）日：2005-01-20

  The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R 1 is an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkenyl group, a cycloalkyl group or a lower acyl group etc.; Q is a hydrogen atom or an optionally substituted lower alkyl group; and Z is a hydrogen atom or a hydroxy group etc., or a pharmaceutically acceptable salt thereof, which exert a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same and an intermediate thereof. These compounds are useful as preventives or remedies for various diseases such as brain infarction, cerebral thrombosis, cerebral embolism, TIA, cerebral vascular jerk, Alzheimer's diseases, myocardial infarction, heart attack, heart failure, thrombosis, pulmonary infarction and pulmonary embolism.

  本发明涉及一种5-酰胺基-2-羟基苯磺酰胺衍生物，其通式表示为：其中，R1是可选取的取代的低烷基，可选取的取代的低烷氧基，可选取的取代的低烯基，环烷基或低酰基等；Q是氢原子或可选取的取代的低烷基；Z是氢原子或羟基等，或其药学上可接受的盐。该衍生物具有强效和选择性的激活血凝因子X抑制活性，可用作预防或治疗与激活血凝因子X相关的疾病的药物，以及包含该衍生物和其中间体的制药组合物。这些化合物可用作各种疾病的预防或治疗，例如脑梗死、脑血栓形成、脑栓塞、短暂性脑缺血发作、脑血管抽搐、阿尔茨海默病、心肌梗死、心脏病发作、心力衰竭、血栓形成、肺梗死和肺栓塞。
• Pharmaceutical compounds
  申请人：Shuttleworth Stephen J.

  公开号：US20080207611A1

  公开（公告）日：2008-08-28

  Fused pyrimidines of formula (I): wherein R 1 -R 3 , A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof, have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

  公式（I）的融合嘧啶： 其中R1-R3，A和n具有规范中描述的任何值；以及其药学上可接受的盐，具有作为PI3K抑制剂的活性，因此可用于治疗由与PI3激酶相关的异常细胞生长，功能或行为引起的疾病和障碍，如癌症，免疫障碍，心血管疾病，病毒感染，炎症，代谢/内分泌障碍和神经障碍。还描述了合成该化合物的过程。
• Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same
  申请人：Vu Chi

  公开号：US20080070932A1

  公开（公告）日：2008-03-20

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagofiists. thereof for preventing and/or treating numerous diseases, including C) Parkinson's disease. In one embodiment, the invention features a compound of formual (I).

  该发明基于发现，式（I）化合物具有意外的高亲和力，可用作A2a腺苷受体的拮抗剂，可用于预防和/或治疗包括帕金森病在内的许多疾病。在一种实施例中，该发明涉及式（I）化合物。
• Triazolotriazines and pyrazolotriazines and methods of making and using the same
  申请人：Vu Chi

  公开号：US20060276475A1

  公开（公告）日：2006-12-07

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A 2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I: (I)

  该发明基于发现，化合物(I)的公式具有意外的高亲和力，可用作拮抗剂，用于预防和/或治疗许多疾病，包括帕金森病的A2a腺苷受体。在一种实施例中，该发明涉及公式I的化合物：(I)。